Skip to main content
AAN.com
Articles
February 16, 2009

“Disease-modification” trials in Parkinson disease: Target populations, endpoints and study design

February 17, 2009 issue
72 (7_supplement_2) S51-S58

Abstract

“Neuroprotective” compounds that block dopamine cell death are expected to slow the progression of the neurologic symptoms of Parkinson disease (PD) and therefore “modify” the disease course. However, presently, no fully satisfying efficacy “disease-modification” study design exists, and no drug has yet been approved for that indication. This is inherent to the slow progression of PD with respect to the limited time for patient follow-up and exposure to placebo, the modest effects of investigated drugs, and the confounding effects of symptomatic medications used to treat patients with PD. Disease-modification trials assessing drug efficacy on PD progression are currently prospective, randomized, parallel-group, placebo-controlled, long-term (1–3 year) studies. Untreated patients with early PD represent the main target population because more neurons remain for protection, PD may progress faster, and symptomatic medications are not needed at this stage. “Long lasting” prevention/postponement of disability is a relevant objective for such trials and two main types of outcome and analysis are proposed: slopes analysis of cardinal clinical feature progression (Unified PD Rating Scale, UPDRS) or survival curve analysis of “time to emergence” of clinically relevant milestones (time to dopaminergic therapy, Hoehn and Yahr stage III, etc.). The use of biomarkers remains investigational. Wash-out and delayed-start designs have been proposed to disentangle symptomatic and neuroprotective mechanisms, although this clarification might not be so important practically, as long as the effect on disability is large and long-lasting. To observe clinically relevant changes, several years of follow-up is required, and controlled, randomized, pragmatic trials should be considered when establishing clinical development plans.

Get full access to this article

View all available purchase options and get full access to this article.

REFERENCES

1.
Movement Disorder Society task force. Management of Parkinson's disease: an evidence-based review. Mov Disord 2002;17(Suppl 4):S1–S166.
2.
Goetz CG, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord 2005;20:523–539.
3.
Lang AE. The progression of Parkinson disease: a hypothesis. Neurology 2007;68:948–952.
4.
Hirsch EC. How to judge animal models of Parkinson's disease in terms of neuroprotection. J Neural Transm Suppl 2006;70:255–260.
5.
Poewe WH, Wenning GK. The natural history of Parkinson's disease. Ann Neurol 1998;44(3 Suppl 1):S1–S9.
6.
Alves G, Wentzel-Larsen T, Aarsland D, Larsen JP. Progression of motor impairment and disability in Parkinson disease: a population-based study. Neurology 2005;65:1436–1441.
7.
Braak H, Del Tredici K. Invited article: Nervous system pathology in sporadic Parkinson's disease. Neurology 2008;70:1916–1925.
8.
Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 2001;57:1497–1499.
9.
Hilker R, Schweitzer K, Coburger S, et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol 2005;62:378–382.
10.
Nutt JG, Carter JH, Van Houten L, Woodward WR. Short- and long-duration responses to levodopa during the first year of levodopa therapy. Ann Neurol 1997;42:349–355.
11.
Olanow CW, Hauser R, Jankovic J, et al. A randomized, double-blind, placebo-controlled delayed start study to assess rasagiline as a disease-modification therapy in Parkinson's disease (the ADAGIO study): rationale, design and baseline characteristics. Mov Disord 2008;23:2194–2201.
12.
Schapira AH, Obeso J. Timing of treatment initiation in Parkinson's disease: a need for reappraisal? Ann Neurol 2006;59:559–562.
13.
Schrag A. Epidemiology of movement disorders. In: Jankovic J, Tolosa E, eds. Parkinson's Disease and Movement Disorders.
14.
Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287:1653–1661.
15.
Whone AL, Watts RL, Stoessl AJ, et al. REAL-PET Study Group. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003;54:93–101.
16.
Fahn S, Oakes D, Shoulson I, et al. Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498–2508.
17.
Schneider SA, Edwards MJ, Mir P, et al. Patients with adult-onset dystonic tremor resembling parkinsonian tremor have scans without evidence of dopaminergic deficit (SWEDDs). Mov Disord 2007;22:2210–2215.
18.
Tolosa E, Gaig C, Santamaria J, Compta Y. Diagnosis and the premotor phase of Parkinson disease. Neurology 2009; 72(Suppl 2): S12–S20.
19.
Siderowf A, Stern MB. Preclinical diagnosis of Parkinson's disease: are we there yet? Curr Neurol Neurosci Rep 2006;6:295–301.
20.
Sampaio C, Rascol O. In: Jankovic J, Tolosa E, eds. Parkinson's disease and movement disorders.
21.
Fahn S, Elton R, Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent Developments in Parkinson's Disease. Vol. II. Florham Park, NJ: Macmillan Health Care Information;
22.
Schrag A, Sampaio C, Counsell N, Poewe W. Minimal clinically important change on the unified Parkinson's disease rating scale. Mov Disord 2006;21:1200–1207.
23.
Rascol O. Defining a minimal clinically relevant difference for the unified Parkinson's rating scale: an important but still unmet need. Mov Disord 2006;21: 1059–1061.
24.
Goetz CG, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): process, format, and clinimetric testing plan. Mov Disord 2007;22:41–47.
25.
Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427–442.
26.
Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989;321:1364–1371.
27.
Hely MA, Morris JG, Traficante R, Reid WG, O'Sullivan DJ, Williamson PM. The Sydney multicentre study of Parkinson's disease: progression and mortality at 10 years. J Neurol Neurosurg Psychiatry 1999;67:300–307.
28.
Marttila RJ, Rinne UK. Disability and progression in Parkinson's disease. Acta Neurol Scand 1977;56:159–169.
29.
Müller J, Wenning GK, Jellinger K, McKee A, Poewe W, Litvan I. Progression of Hoehn and Yahr stages in Parkinsonian disorders: a clinicopathologic study. Neurology 2000;55:888–891.
30.
Lücking CB, Dürr A, Bonifati V, et al. French Parkinson's Disease Genetics Study Group; European Consortium on Genetic Susceptibility in Parkinson's Disease. Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med 2000;342:1560–1567.
31.
Bejjani BP, Gervais D, Arnulf I, et al. Axial parkinsonian symptoms can be improved: the role of levodopa and bilateral subthalamic stimulation. J Neurol Neurosurg Psychiatry 2000;68:595–600.
32.
Rascol O. Medical treatment of levodopa-induced dyskinesias. Ann Neurol 2000;47(4 Suppl 1):S179–S188.
33.
Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 2000;284:1931–1938.
34.
Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE; 056 Study Group. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000;342:1484–1491.
35.
Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89–95.
36.
Wagner JA. Strategic approach to fit-for-purpose biomarkers in drug development. Annu Rev Pharmacol Toxicol 2008;48:631–651.
37.
Wagner JA, Williams SA, Webster CJ. Biomarkers and surrogate endpoints for fit-for-purpose development and regulatory evaluation of new drugs. Clin Pharmacol Ther 2007;81:104–107.
38.
Michell AW, Lewis SJ, Foltynie T, Barker RA. Biomarkers and Parkinson's disease. Brain 2004;127(Pt 8):1693– 1705.
39.
Schwarzschild MA, Schwid SR, Marek K, et al. Parkinson Study Group PRECEPT Investigators, Hyson C, Gorbold E, Rudolph A, et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol 2008;65:716–723.
40.
Ravina B, Eidelberg D, Ahlskog JE, et al. The role of radiotracer imaging in Parkinson disease. Neurology 2005;64:208–215.
41.
Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001;344:710–719.
42.
Tilley BC, Palesch YY, Kieburtz K, et al. NET-PD Investigators. Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs. Neurology 2006;66:628–633.
43.
Mehta CR, Tsiatis AA. Flexible sample size considerations using information-based interim monitoring. Drug Inf J 2001;35:1095–1112.
44.
Müller HH, Schäfer H. Adaptive group sequential designs for clinical trials: combining the advantages of adaptive and classical group sequential approaches. Biometrics 2001;57:886–891.
45.
Wheatley K, Stowe RL, Clarke CE, Hills RK, Williams AC, Gray R. Evaluating drug treatment for Parkinson's disease: how good are the trials? BMJ 2002;324:1508–1511.
46.
Fahn S; and the Parkinson Study Group. Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol 2005;252(Suppl 4):IV37–IV42.
47.
Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995;38:771–777.
48.
Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176–183.
49.
Leber P. Slowing the progression of Alzheimer disease: methodological issues. Alzheimer Dis Assoc Disord 1997;11(Suppl 5):S10–S21; discussion S37–S39.
50.
Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004;61:561–566.
51.
Olanow CW, Rascol O. Early rasagiline treatment slows decline in the ADAGIO delayed start study. Ann Neurol 2008;64(Suppl 12):S68. Abstract.
52.
Clarke CE. Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed? Mov Disord 2008;23:784–789.

Information & Authors

Information

Published In

Neurology®
Volume 72Number 7_supplement_2February 17, 2009
Pages: S51-S58
PubMed: 19221315

Publication History

Published online: February 16, 2009
Published in print: February 17, 2009

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

Olivier Rascol, MD, PhD
From the University Hospital of Toulouse, Clinical Investigation Center, Departments of Neurosciences and Clinical Pharmacology, INSERM UMR 825, Toulouse, France.

Notes

Address correspondence and reprint requests to Olivier Rascol, MD, PhD, University Hospital of Toulouse, Clinical Investigation Center, Departments of Neurosciences and Clinical Pharmacology, INSERM UMR 825, Toulouse, France [email protected]

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Role of Animal Models in Parkinson's Disease (PD): What Role They Play in Preclinical Translational Research, CNS & Neurological Disorders - Drug Targets, 23, 2, (181-202), (2024).https://doi.org/10.2174/1871527322666230223150347
    Crossref
  2. Role of novel endpoints and evaluations of response in Parkinson disease, Precision Medicine in Neurodegenerative Disorders, Part II, (325-345), (2023).https://doi.org/10.1016/B978-0-323-85555-6.00010-2
    Crossref
  3. The dilemma between milestones of progression versus clinical scales in Parkinson's disease, Precision Medicine in Neurodegenerative Disorders, Part I, (169-185), (2023).https://doi.org/10.1016/B978-0-323-85538-9.00010-9
    Crossref
  4. Evaluation of a Structured Screening Assessment to Detect Isolated Rapid Eye Movement Sleep Behavior Disorder, Movement Disorders, 38, 6, (990-999), (2023).https://doi.org/10.1002/mds.29389
    Crossref
  5. Author Response: Long-term Effect of Regular Physical Activity and Exercise Habits in Patients With Early Parkinson Disease, Neurology, 99, 3, (133-134), (2022)./doi/10.1212/WNL.0000000000200925
    Abstract
  6. Clinical trials in REM sleep behavioural disorder: challenges and opportunities, Journal of Neurology, Neurosurgery & Psychiatry, 91, 7, (740-749), (2020).https://doi.org/10.1136/jnnp-2020-322875
    Crossref
  7. Clinical Trials for Disease-Modifying Agents in Parkinson’s Disease, Clinical Trials In Parkinson's Disease, (161-175), (2020).https://doi.org/10.1007/978-1-0716-0912-5_7
    Crossref
  8. Seven Solutions for Neuroprotection in Parkinson's Disease, Movement Disorders, 36, 2, (306-316), (2020).https://doi.org/10.1002/mds.28379
    Crossref
  9. Use of β2-adrenoreceptor agonist and antagonist drugs and risk of Parkinson disease, Neurology, 93, 2, (e135-e142), (2019)./doi/10.1212/WNL.0000000000007694
    Abstract
  10. Preventing and Slowing the Progression of Parkinson's: A Clinical Conversation with Laurie Mischley, ND, MPH, PhD, and Robert Rountree, MD, Alternative and Complementary Therapies, 25, 2, (59-67), (2019).https://doi.org/10.1089/act.2019.29208.lmi
    Crossref
  11. See more
Loading...

View Options

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

Purchase this article to get full access to it.

Purchase Access, $39 for 24hr of access

View options

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share